A prostaglandin E composition comprises are substantially free from C.sub.1-C.sub.4 alcohols and include the prostaglandin E compound together with a (C.sub.1-C.sub.4)-alkyl(C.sub.8-C.sub.22)carboxylic ester (e.g., ethyl laurate), an N,N-di(C.sub.1-C.sub.8)alkylamino substituted, (C.sub.4-C.sub.18)alkyl(C.sub.2-C.sub.18)carboxylic ester and/or a pharmaceutically acceptable addition salt thereof, and optionally, a viscosity enhancing agent such as guar gum. The prostaglandin E composition can be combined with an aqueous alcoholic diluent to form a pharmaceutical composition for topical application to a patient, for example, to treat sexual dysfunction. The prostaglandin E compositions are stable for prolonged periods of storage at room temperature.